Skip to main content

Table 4 The univariate and multivariate analyses for relapse

From: Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer

Parameter (Favorable vs. Unfavorable)UnivariateMultivariate
 Including
SUVmax1
Including
ΔSUVmax%
Including
SUVmax1/ΔSUVmax%
Hazard ratioP-valueHazard ratioP-valueHazard ratioP-valueHazard ratioP-value
(95% CI)(95% CI)(95% CI)(95% CI)
Pathological T factor4.9< 0.00012.350.02292.50.01552.210.0392
 (pT2, pT3 vs. pTis, pT1)(2.48–10.3)(1.12–5.24)(1.18–5.62)(1.03–5.02)
Nuclear grade4.79< 0.00012.460.03032.790.01252.570.0222
 (3 vs. 1, 2)(2.34–10.7)(1.08–6.10)(1.23–6.97)(1.13–6.39)
Lymphovascular invasion7.32< 0.00014.830.00074.360.00154.920.0006
 (Positive vs. Negative)(3.28–19.5)(1.87–14.6)(1.70–13.0)(1.90–14.9)
Estrogen receptor1.460.339      
 (Negative vs. Positive)(0.65–2.97)      
Progesterone receptor1.340.404      
 (Negative vs. Positive)(0.65–2.63)      
HER21.080.879      
 (Positive vs. Negative)(0.32–2.73)      
Ki-67 labeling index3.380.00121.620.2471.830.1391.680.212
 (≥ 14.0 vs. < 14.0)(1.58–8.06)(0.72–4.04)(0.83–4.50)(0.75–4.18)
Pathological N factor4.47< 0.00011.520.2611.520.2681.510.276
 (pN1, pN2, pN3 vs. pN0)(2.32–8.92)(0.73–3.32)(0.73–3.35)(0.72–3.30)
SUVmax13.610.00032.540.0267    
 (≥ 3.4 vs. <  3.4)(1.77–8.13)(1.10–6.46)    
ΔSUVmax%2.460.0122  1.740.152  
 (≥ 12.5 vs. <  12.5)(1.20–5.53)  (0.82–4.07)  
SUVmax1/ΔSUVmax%3.240.0007    2.330.0283
 (Group A vs. Group B/C)(1.62–6.72)    (1.09–5.31)
  1. CI, confidence interval
  2. HER2, human epidermal growth factor receptor 2
  3. SUV, standardized uptake value